Similarly, inhibitors of chemokine receptors such as CXCR1/2 and CCR2/5 are being investigated as potential anti-cancer agents, with the aim of disrupting tumor-promoting inflammatory responses and inhibiting metastasis[29]. This evidence concerns the gene CXCR1 and neoplasm.